VCM
REGN icon

Versant Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Versant Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$214K Sell
344
-68
-17% -$46.3K 0.02% 594
2026
Q1 		$318K Buy
412
+141
+52% +$108K 0.03% 414
2025
Q4 		$209K Buy
271
+15
+6% +$10.2K 0.03% 478
2025
Q3 		$144K Buy
256
+85
+50% +$48.1K 0.02% 585
2025
Q2 		$89.8K Sell
171
-55
-24% -$30.7K 0.01% 715
2025
Q1 		$143K Buy
226
+174
+335% +$120K 0.02% 511
2024
Q4 		$37K Sell
52
-27
-34% -$22.7K 0.01% 702
2024
Q3 		$83K Buy
79
+11
+16% +$12.2K 0.02% 286
2024
Q2 		$71.5K Buy
68
+37
+119% +$35.9K 0.02% 281
2024
Q1 		$29.8K Hold
31
– – 0.01% 382
2023
Q4 		$27.2K Sell
31
-2
-6% -$1.65K 0.01% 391
2023
Q3 		$27.2K Buy
33
+1
+3% +$786 0.01% 392
2023
Q2 		$23K Buy
32
+3
+10% +$2.31K 0.01% 466
2023
Q1 		$23.8K Hold
29
– – 0.01% 432
2022
Q4 		$20.9K Sell
29
-1
-3% -$738 0.01% 435
2022
Q3 		$21K Hold
30
– – 0.01% 414
2022
Q2 		$18K Sell
30
-1
-3% -$650 0.01% 465
2022
Q1 		$22K Hold
31
– – 0.01% 447
2021
Q4 		$20K Hold
31
– – 0.01% 501
2021
Q3 		$19K Hold
31
– – 0.01% 492
2021
Q2 		$17K Buy
31
+17
+121% +$8.61K 0.01% 538
2021
Q1 		$7K Buy
14
+7
+100% +$3.41K ﹤0.01% 923
2020
Q4 		$3K Hold
7
– – ﹤0.01% 1062
2020
Q3 		$3K Hold
7
– – ﹤0.01% 1004
2020
Q2 		$4K Hold
7
– – ﹤0.01% 924
2020
Q1 		$3K Sell
7
-3
-30% -$1.24K ﹤0.01% 939
2019
Q4 		$3K Sell
10
-3
-23% -$1.01K ﹤0.01% 1076
2019
Q3 		$3K Hold
13
– – ﹤0.01% 1105
2019
Q2 		$4K Sell
13
-4
-24% -$1.33K ﹤0.01% 1046
2019
Q1 		$6K Hold
17
– – ﹤0.01% 1066
2018
Q4 		$6K Hold
17
– – ﹤0.01% 980
2018
Q3 		$6K Hold
17
– – ﹤0.01% 1051
2018
Q2 		$5K Hold
17
– – ﹤0.01% 1093
2018
Q1 		$5K Hold
17
– – ﹤0.01% 1077
2017
Q4 		$6K Hold
17
– – ﹤0.01% 1077
2017
Q3 		$7K Sell
17
-3
-15% -$1.43K ﹤0.01% 971
2017
Q2 		$9K Hold
20
– – 0.01% 903
2017
Q1 		$7K Hold
20
– – ﹤0.01% 961
2016
Q4 		$7K Sell
20
-3
-13% -$1.14K ﹤0.01% 945
2016
Q3 		$9K Buy
23
+2
+10% +$802 0.01% 853
2016
Q2 		$7K Sell
21
-5
-19% -$1.93K ﹤0.01% 893
2016
Q1 		$9K Buy
26
+2
+8% +$824 0.01% 798
2015
Q4 		$13K Buy
+24
New +$13K 0.01% 658

Other funds holding REGN

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
AIP
ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return
HCM
Howland Capital Management Boston, Massachusetts $2.77B AUM 19.56% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Versant Capital Management's REGN Position: Q2 2026 in Review

Versant Capital Management reduced its Regeneron Pharmaceuticals (REGN) stake by 17% in Q2 2026, selling an estimated $46.3K and leaving 344 shares worth $214K. The position accounts for 0.02% of the portfolio, ranked #594.

Versant Capital Management first reported a position in REGN in Q4 2015 and has held it in 43 quarters since. The position peaked at $318K in Q1 2026. 210 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Versant Capital Management held 344 shares of Regeneron Pharmaceuticals worth $214K as of Q2 2026.
  • Versant Capital Management sold 68 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $46.3K.
  • Regeneron Pharmaceuticals made up 0.02% of Versant Capital Management's portfolio in Q2 2026, its #594 holding.
  • Versant Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2015 and has held it in 43 quarters since.
  • Versant Capital Management's Regeneron Pharmaceuticals position peaked at $318K in Q1 2026.
  • 210 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.